<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82640">
  <stage>Registered</stage>
  <submitdate>27/02/2008</submitdate>
  <approvaldate>11/03/2008</approvaldate>
  <actrnumber>ACTRN12608000128392</actrnumber>
  <trial_identification>
    <studytitle>Modafinil Use in Mild-Moderate Obstructive Sleep Apnea patients.</studytitle>
    <scientifictitle>Effectiveness of modafinil in improving deficits of daytime sleepiness in a randomised crossover trial in mild to moderate obstructive sleep apnea patients.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>There is no secondary ID</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive sleep apnea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose of 200 mg modafinil once per day for 2 weeks with a 2 week washout. Mode of administration of study drug (modafinil &amp; placebo) is oral.</interventions>
    <comparator>Placebo (placebo is a Sugar pill). Dosage frequency is one placebo per day The duration of the control treatment is 2 weeks with a 2-week washout period.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Outcome: Mean Epworth Sleepiness Scale (ESS) score</outcome>
      <timepoint>Crossover trial comparing changes from each baseline until end of treatment 2 weeks later</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>AusEd Driving simulator 40 minute drive. The outcome variable is the mean steering deviation from the drivers median lane position.</outcome>
      <timepoint>Crossover trial comparing changes from each baseline until end of treatment 2 weeks later</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Crossover trial comparing changes from each baseline until end of treatment 2 weeks later</outcome>
      <timepoint>Crossover trial comparing changes from each baseline until end of treatment 2 weeks later</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must be aged 18 to 70, diagnosed obstructive sleep apnea by night polysomnography (apnea-Hypopnea Index =5, = 30), refuse or cannot tolerate a continuous positive airway pressure device and/or a mandibular advancement splint and Epworth Sleepiness Score = 10.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients will be excluded if they are suffering from any uncontrolled concurrent medical or psychiatric illness or if they are currently taking any medications that are known to affect sleep, or that may cause a drug interaction with modafinil; has medical conditions that would contraindicate administration of modafinil (eg, major anxiety, unstable hypertension, coronary artery disease) or has irregular sleep patterns, such as shift-workers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After written consent patients will be enrolled in a randomised order placebo-controlled crossover double blind study. At the end of the baseline visit patients will be randomly assigned, by equal chance, either 200mg modafinil or placebo (1:1 basis). All patients will receive 2 weeks of 200mg modafinil and 2 weeks of placebo, in a crossover fashion.</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software (i.e., computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2008</anticipatedstartdate>
    <actualstartdate>1/10/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/11/2012</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>PO Box M77
Missenden Road 
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Woolcock Institute of Medical Research</fundingname>
      <fundingaddress>PO Box M77
Missenden Road 
Camperdown NSW 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Sydney Bridging Grant 2010</fundingname>
      <fundingaddress>University of Sydney Camperdown 2006 NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to investigate modafinils efficacy to improve parameters of daytime sleepiness and neurocognitive ability in untreated patients with mild to moderate OSA.</summary>
    <trialwebsite />
    <publication>Chapman JL, Kempler L, Chang C, Williams S, Sivam S, Wong KKH, Yee BJ, Grunstein RR, Marshall NS. Modafinil improves daytime sleepiness in patients with mild-to-moderate obstructive sleep apnoea not using standard treatments. A randomised, placebo-controlled, crossover trial. 2014 THORAX 69 274-9.
http://www.ncbi.nlm.nih.gov/pubmed/24287166</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Services (SSWAHS) Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>c/- Research Development Office
Level 8
Building 14
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>27/02/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Ron Grunstein</name>
      <address>Woolcock Institute of Medical Research
PO Box M77
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 95158630</phone>
      <fax>+61 2 95157070</fax>
      <email>swilliams@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Dr Nathaniel Marshall</name>
      <address>Woolcock Institute of Medical Research
PO Box M77
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 02 9351 0829</phone>
      <fax>No fax number</fax>
      <email>nathaniel.marshall@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Julia Chapman</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 9114 0449</phone>
      <fax>+ 61 2 9114 0011</fax>
      <email>julia.chapman@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ron Grunstein</name>
      <address>Woolcock Institute for Medical Research
PO Box M77 Missenden Rd Camperdown NSW 2050</address>
      <phone>+61 2 9114 0000</phone>
      <fax />
      <email>ron.grunstein@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>